Detalhe da pesquisa
1.
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Int J Cancer
; 151(11): 1978-1988, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833561
2.
CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
Mod Pathol
; 35(12): 2002-2010, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36202996
3.
An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.
Mod Pathol
; 35(3): 427-437, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34545179
4.
Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Int J Mol Sci
; 23(8)2022 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35457245
5.
Special features of sarcomas developed in patients with Lynch syndrome: A systematic review.
Crit Rev Oncol Hematol
; 188: 104055, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301271
6.
The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity.
NAR Cancer
; 5(2): zcad011, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36915289